Affiliation:
1. Department of Internal Medicine D, Kaplan Medical Center, Rehovot 7612001, Israel
2. Faculty of Medicine, Hebrew University, Jerusalem 9112001, Israel
3. Institute of Hematology, Kaplan Medical Center, Rehovot 7612001, Israel
Abstract
Febrile neutropenia (FN) is one of the most important life-threatening complications in haemato-oncology. Our objective was to report all-cause mortality rates in patients ill with a hematological malignancy (HM) hospitalized with a first FN episode and to identify predictors for mortality. We conducted a historical retrospective cohort study of consecutive patients with an HM, >18 years of age, admitted between January 2012 and August 2018 for a first episode of FN. Data on all-cause mortality 12 months after admission for FN were obtained. The Kaplan–Meier curve was used to describe mortality during the follow-up period. Univariate and multivariable analyses identified predictors for 1,3 and 12-month mortality. One hundred and fifty-eight patients (mean age 69.5, 49.4% males) were included. Overall, 54 patients died (15.8%, 25.9%, and 34.1% died after 1, 3, and 12 months, respectively). Lower serum albumin, higher serum gamma-glutamyl transferase (GGT), lower estimated glomerular filtration rate (eGFR), older age, higher temperature, and lower absolute lymphocyte count at admission were independent predictors of all-cause mortality after 12 months. Further studies are needed to confirm our results and identify therapeutic strategies to improve survival.
Reference45 articles.
1. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients;Kuderer;Cancer,2006
2. Febrile neutropenia in hematologic malignancies;Keng;Curr. Hematol. Malig. Rep.,2013
3. Epidemiology and source of infection in patients with febrile neutropenia: A ten-year longitudinal study;Hinedi;J. Infect. Public Health,2019
4. Parodi, R.L., Lagrutta, M., Tortolo, M., Navall, E., Rodriguez, M.S., Sasia, G.F., De Candia, L.F., Gruvman, M.A., Bottasso, O., and Greca, A.A. (2019). A multicenter prospective study of 515 febrile neutropenia episodes in Argentina during a 5-year period. PLoS ONE, 14.
5. Factors associated with survival outcomes of febrile neutropenia in hematologic malignancy patients;Weerasubpong;J. Med. Assoc. Thai.,2016